Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

  • End date
    Jun 1, 2023
  • participants needed
  • sponsor
    Hongchang Guo
Updated on 24 January 2021
cardiovascular disease
bypass graft
postoperative complication
sglt2 inhibitor
heart transplantation


Patients with diabetes have poorer cardiac surgery outcomes compared with non-diabetics. Proper blood glucose management is critical to reduce the morbidity and mortality for diabetic patients after cardiac surgery.

SGLT2 inhibitors including dapagliflozin as a new diabetes drug can reduce heart failure hospitalization rates and overall cardiovascular mortality in patients with cardiovascular disease.

This study is to assess the impact of one year of treatment of SGLT2 inhibitors on cardiac function, postoperative complications and long-term cardiovascular mortality in diabetic patients undergoing cardiac surgery.

The investigators use echocardiography to evaluated cardiac function in diabetic patients during perioperative cardiac surgery.

Condition NIDDM, Thoracic Surgery, heart surgery, Diabetes Mellitus, Type 2, Cardiac Surgery, Diabetes Mellitus Type 2, type 2 diabetes mellitus, cardiac operation, type 2 diabetes, type ii diabetes, noninsulin-dependent diabetes mellitus, diabetes type 2
Treatment placebos, Dapagliflozin 10 mg
Clinical Study IdentifierNCT04340908
SponsorHongchang Guo
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Diabetes Mellitus, Type 2 or heart surgery or Thoracic Surgery or Diabetes Mellitus Type 2 or NIDDM or Cardiac Surgery?
Do you have any of these conditions: Diabetes Mellitus Type 2 or diabetes type 2 or type 2 diabetes mellitus or NIDDM or cardiac operation or Diabetes Mellitus, Type 2 or noninsulin-depen...?
Age 18 years old at index date
Diagnosis of Type 2 Diabetes
Scheduled for cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy)
eGFR 60 ml/min/1.73 m2
Patients who agree to receive treatment with SGLT2 inhibitors
Patients must be on current stable hemodynamic profile , without dehydration

Exclusion Criteria

Diagnosis of Type 1 Diabetes
eGFR < 60 ml/min/1.73 m2
Unstable or rapidly progressive renal disease
Hypersensitivity to dapagliflozin or any excipients
Severe hepatic disease
Patients who have participated in any other clinical trial of an investigational medicinal product within the previous 30 days
Any other reason considered by a study physician to be inappropriate for inclusion
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note